Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micro Therapeutics CE-marks liquid embolic system:

This article was originally published in Clinica

Executive Summary

Micro Therapeutics has CE-marked its ONYX liquid embolic system for the endovascular treatment of arteriovenous malformations (AVMs) in the brain, abnormal formations of arteries and veins that are prone to rupturing. ONYX, previously called EMBOLYX, acts as a vascular "blocking agent". It is delivered in a liquid form via microcatheters to the intended site where it quickly transforms into a solid polymer mass, filling the targeted vascular malformation. The Irvine, California-based company said that US firm Guidant will market the product in most of Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel